Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 319-334

  Sato, Takashi ^a,b   Arai, Eri ^a   Kohno, Takashi ^a   Takahashi, Yoriko ^c   Miyata, Sayaka ^c   Tsuta, Koji ^d   Watanabe, Shun Ichi ^d   Soejima, Kenzo ^b   Betsuyaku, Tomoko ^b   Kanai, Yae ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Mitsui Knowledge Industry Co   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

chronic obstructive pulmonary disease; cigarette smoking; DNA methylation; infinium assay; lung adenocarcinoma

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER TISSUE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; DNA PROBE; EI24 GENE; EPIGENETICS; FEMALE; HISTOPATHOLOGY; HOXD8 GENE; HUMAN; HUMAN TISSUE; IRX2 GENE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RGS5 GENE; SMOKING; SPARCL1 GENE; TUMOR GENE; TUMOR INVASION; VALIDATION STUDY;

ADENOCARCINOMA; ADULT; AGED; CLUSTER ANALYSIS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84900016421     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28684     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Sun S, Schiller JH, Gazdar AF,. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007; 7: 778-90.
3. Baylin SB, Jones PA,. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-34.
4. Heller G, Zielinski CC, Zochbauer-Muller S,. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev 2010; 29: 95-107.
5. Arai E, Kanai Y,. DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status. Epigenomics 2010; 2: 467-81.
6. Kanai Y,. Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci 2010; 101: 36-45.
7. Arai E, Chiku S, Mori T, et al. Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis 2012; 33: 1487-93.
8. Zöchbauer-Müller S, Lam S, Toyooka S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 2003; 107: 612-6.
9. Eguchi K, Kanai Y, Kobayashi K, et al. DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history. Cancer Res 1997; 57: 4913-5.
10. Lamy A, Sesboüé R, Bourguignon J, et al. Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer. Int J Cancer 2002; 100: 189-93.
11. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002; 62: 2370-7.
12. Bibikova M, Le J, Barnes B, et al. Genome-wide DNA methylation profiling using Infinium(R) assay. Epigenomics 2009; 1: 177-200.
13. Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 2012; 22: 1197-211.
14. Lockwood WW, Wilson IM, Coe BP, et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One 2012; 7: e37775.
15. Sato T, Arai E, Kohno T, et al. DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma. PLoS One 2013; 8: e59444.
16. Nagashio R, Arai E, Ojima H, et al. Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. Int J Cancer 2011; 129: 1170-9.
17. Arai E, Ushijima S, Gotoh M, et al. Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. Int J Cancer 2009; 125: 2854-62.
18. Ushijima T, Hattori N,. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin Cancer Res 2012; 18: 923-9.
19. Kanai Y, Hirohashi S,. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 2007; 28: 2434-42.
20. Garibaldi BT, Illei P, Danoff SK,. Bronchiolitis. Immunol Allergy Clin North Am 2012; 32: 601-19.
21. Travis WD, Colby TV, Koss MN, et al. Obstructive pulmonary disease. In: King DW, ed. Atlas of nontumor pathology. Non-neoplastic disorders of the lower respiratory tract. Washington, DC: American Registry of Pathology, 2002:4 35-71.
22. Kerr KM,. Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification. J Clin Pathol 2013; 66: 832-8.
23. Noguchi M, Shimosato Y,. The development and progression of adenocarcinoma of the lung. Cancer Treat Res 1995; 72: 131-42.
24. Colby TV, Noguchi M, Henschke C, et al. Adenocarcinoma. In:, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World health classification of tumours pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004: 35-44.
25. Wang D, Minami Y, Shu Y, et al. The implication of background anthracosis in the development and progression of pulmonary adenocarcinoma. Cancer Sci 2003; 94: 707-11.
26. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75: 2844-52.
27. UICC International Union Against Cancer. Lung and pleural tumours. In:, Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM classification of malignant tumours, 7th edn. Oxford: Wiley-Blackwell, 2009: 138-46.
28. Hu L, Sekine M, Gaina A, et al. Association of smoking behavior and socio-demographic factors, work, lifestyle and mental health of Japanese civil servants. J Occup Health 2007; 49: 443-52.
29. Kadara H, Kabbout M, Wistuba II,. Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 2012; 17: 50-65.
30. Decramer M, Janssens W, Miravitlles M,. Chronic obstructive pulmonary disease. Lancet 2012; 379: 1341-51.
31. Peng DF, Kanai Y, Sawada M, et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 2006; 27: 1160-8.
32. Peng DF, Kanai Y, Sawada M, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci 2005; 96: 403-8.
33. Suzuki M, Wada H, Yoshino M, et al. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol 2010; 17: 878-88.
34. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-81.
35. Mummenhoff J, Houweling AC, Peters T, et al. Expression of Irx6 during mouse morphogenesis. Mech Dev 2001; 103: 193-5.
36. Leshchenko VV, Kuo PY, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010; 116: 1025-34.
37. Kanai M, Hamada J, Takada M, et al. Aberrant expressions of HOX genes in colorectal and hepatocellular carcinomas. Oncol Rep 2010; 23: 843-51.
38. Hurley PJ, Marchionni L, Simons BW, et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci USA 2012; 109: 14977-82.
39. Turtoi A, Musmeci D, Naccarato AG, et al. Sparc-like protein 1 is a new marker of human glioma progression. J Proteome Res 2012; 11: 5011-21.
40. Jin Y, An X, Ye Z, et al. RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells. J Biol Chem 2009; 284: 23436-43.
41. Huang G, Song H, Wang R, et al. The relationship between RGS5 expression and cancer differentiation and metastasis in non-small cell lung cancer. J Surg Oncol 2012; 105: 420-4.
42. Wang JH, Huang WS, Hu CR, et al. Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma. World J Gastroenterol 2010; 16: 5642-6.
43. Zhao X, Ayer RE, Davis SL, et al. Apoptosis factor EI24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness. Cancer Res 2005; 65: 2125-9.